Earlier this year, MIT Technology Review released the list of Breakthrough Technologies 2015. The liquid biopsies are closely linked with life science.

Jay Flately, the CEO of Illumina said the liquid biopsies market will reach 40 billion at least. This technology will be the most exciting breakthrough in cancer diagnosis field.

Recently, MIT Technology Review released an article of What Are Liquid Biopsies Useful For. The article summarizes the 8 fields of liquid biopsies, include Down's syndrome, rare congenital diseases, sex determination, paternity test, cancer therapy, cancer prediction, organ rejection and type I diabetes.

Currently, liquid biopsies already has a certain commercial value, and probably become an important way of cancer detection. In Aug 19, GEN released a report of liquid biopsies, the report said the market of liquid biopsies is growing, and the scientists’ research of the circulating biomarkers used for disease detection and diagnosis also are strengthening.

The report summarized different kinds of circulating biomarkers are driving the development of liquid biopsies. These kinds of circulating biomarkers also compete with each other. Because the FDA approved Veridex/Johnson &Johnson’s CellSearch system used to CTCs, the CTCs is leading the way in this regard.

However, the CTCs can’t provide the patient’s integrated condition. So the researchers have always been searching the other kinds of biomarkers. Circulating DNA and exosome/microvesicle are emerging in this background. And there also need some prospective clinical trials to evaluate the clinical practicability of these kinds of biomarkers.